Zimmer Biomet Holdings (ZBH) was trading at $116.5 as of June 17, 2016. It has a 50-day moving average of $118.5 and a 200-day moving average of $106.1. As of June 17, 2016, Zimmer Biomet Holdings’ stock was trading ~32% above its 52-week low and ~6% below its 52-week high. The company’s share price has risen ~1.5% since the release of its 1Q16 earnings on April 28, 2016.
On June 7, 2016, Zimmer Biomet Holdings announced the acquisition of LDR, which triggered a share price decline. However, the share price of LDR had risen by more than 60% after the acquisition announcement. On June 14, 2016, the company announced its secondary offering of approximately 11.1 million shares at $115.85 per share. The stock price fell ~2% after the announcement. However, the company is expected to generate returns of approximately 8.8% over the next 12 months, according to analyst estimates. The company is expected to generate positive investor sentiments in the long term and witness improvement in stock prices.
Zimmer Biomet Holdings has returned ~5.4% over the last one year. It outperformed the S&P 500 Index, which returned ~1.1% during the same period. The company has registered YTD returns of ~15%.
Peers’ stock performances
As of June 21, 2016, Zimmer Biomet Holdings’ peer companies Johnson & Johnson (JNJ), Medtronic (MDT), and Stryker (SYK) had generated returns of 16.7%, 9.4%, and 19.8%, respectively, over the last 12 months.
The PowerShares S&P 500 Low Volatility Portfolio (SPLV) holds approximately 0.91% of its total holdings in Zimmer Biomet.